11 results about "Epstein bar virus" patented technology

Herpesviridae glycoprotein B (gB) polypeptides comprising a modified ectodomain is stabilized in the prefusion state, enabling development of inhibitors and vaccines directed against these viral pathogens. Modifications to DI, DII, and DV subdomains are important to stabilization of gB in the prefusion state, and additional modifications result in a further improved stabilization of gB in the prefusion state. The gB can be derived from an Epstein Barr Virus (EBV), a Human Cytomegalovirus (CMV), a Human Herpesvirus 6 (HHV6), a Herpes Simplex Virus 1 (HSV1), or a Varicella Zoster Virus (VZV). Polypeptides, nucleic acid constructs, compositions, and methods of using same to elicit an immune response are described.

This disclosure concerns methods of analysing and sequencing viral genomic DNA, in particular Epstein-Barr virus (EBV) genomic DNA, using viral-specific nucleic acid capture probes and long read sequencing.

The present disclosure relates to nucleic acid molecules (e.g., self-replicating RNAs (srRNAs) expressing one or more antigenic determinants derived from Epstein-Barr virus (EBV)), recombinant cells containing the nucleic acid molecules and pharmaceutical compositions, and uses of such srRNA molecules, recombinant cells and compositions for eliciting pharmacodynamic effects in a subject. Methods for preventing and / or treating a variety of health conditions associated with EBV infection are also provided.

Reconstructed Modified Vaccinia Ankara (rMVA) vectors configured to encode stable Epstein Bar Virus (EBV) glycoproteins gp42, gL, gH, gp350, and gB, compositions comprising the rMVA vectors, vaccines comprising the compositions, and methods of preventing EBV infection by administering the vaccines and eliciting an innate and humoral immune response.

Provided herein are engineered Epstein-Barr virus (EBV) polypeptides, polynucleotides encoding the same, related vectors and vaccine compositions, and related methods of making and using said compositions. The compositions disclosed herein may be useful for vaccination against EBV.

In particular, synthetic mRNA is provided that can specifically induce transcription of one or more Epstein-Barr virus (EBV) lysis genes in an EBV infected cell, thereby destroying the cell. Also described herein are methods of synthesizing the mRNA and methods of using the mRNA for the treatment of EBV-related diseases, such as EBV-positive cancer.

The present disclosure provides methods and compositions of modified oligonucleotide primer and probe combinations, structurally modified with locked nucleic acids, quenchers, and dyes, effective to detect tumor-derived Human Papilloma Virus (HPV) and tumor-derived Epstein-Barr virus (EBV) and, especially, to distinguish viral DNA derived from tumors from viral DNA derived from infectious viral particles.

An isolated trifunctional bispecific antibody for use in a method of treating a patient suffering from a disease and / or disorder associated with reactivation of Epstein-Barr virus (EBV) in at least B cells and potentially other susceptible cells, such as susceptible epithelial cells, the method comprising: providing an autologous cell preparation of enriched B cells of the patient; incubating the enriched B cells with a trifunctional bispecific antibody for a period of time sufficient to establish a physical interaction between the trifunctional bispecific antibody and the enriched B cells to obtain an incubation mixture; transferring the incubation mixture obtained after incubation into the same patient, wherein the trifunctional bispecific antibody comprises: (a) a first binding arm binding to B cells via a B cell surface antigen; (b) a second binding arm binding to T cells via a T cell surface antigen; (c) an Fc part binding to Fc receptor positive cells. The invention also discloses a pharmaceutical composition comprising the isolated trifunctional bispecific antibody for use in treating a patient suffering from a disease and / or disorder associated with reactivation of EBV in B cells, and an ex vivo method for the preparation of the pharmaceutical composition.

The present invention relates to modified immune cells expressing T cell receptors (TCR) targeting Epstein-Barr virus (EBV) and their pharmaceutical uses. The present invention provides compositions comprising LMP2A specific TCR-T cell populations for the treatment of EBV-associated cancers and other indications, as well as methods for preparing and using the compositions. The present invention also provides nucleic acid sequences encoding the TCR and vectors thereof. The modified EBV-targeting immune cells of the present invention are activated upon binding tumor cells; they recognize targets and activate T-cell functions depending on presentation by major histocompatibility complex (MHC) molecules, while maintaining proliferation and antitumor activity. The EBV-targeting immune cells have demonstrated favorable antitumor efficacy in preclinical studies, offering a novel therapeutic strategy for patients with EBV-associated cancers.

Provided herein are methods, systems, and computer readable medium for detecting nucleic acid from a pathogen, e.g., virus, e.g., Epstein-Barr virus (EBV), in a cell-free nucleic sample from an individual at risk of a condition, e.g., nasopharyngeal carcinoma (NPC). The methods, systems, and computer readable medium can be used to screen for the presence of the condition, e.g., NPC, using thresholds adjusted based on sample attributes.

Disclosed herein are methods for generating / expanding a population of immune cells comprising immune cells specific for Epstein-Barr virus (EBV) lytic antigens, the methods comprising stimulating immune cells specific for EBV lytic antigens by contacting peripheral blood mononuclear cells (PBMCs) with (i) one or more peptides corresponding to all or a portion of one or more EBV lytic antigens; or (ii) antigen presenting cells (APCs) presenting one or more peptides corresponding to all or a portion of one or more EBV lytic antigens. Also disclosed are populations of immune cells comprising immune cells specific for EBV lytic antigens expanded according to these methods, and uses thereof.